<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">37817031</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-1182</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Molecular neurobiology</Title><ISOAbbreviation>Mol Neurobiol</ISOAbbreviation></Journal><ArticleTitle>Comprehensive Risk Assessment of Infection Induced by SARS-CoV-2.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12035-023-03682-4</ELocationID><Abstract><AbstractText>The pandemic COVID-19 (coronavirus disease 2019) is caused by the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), which devastated the global economy and healthcare system. The infection caused an unforeseen rise in COVID-19 patients and increased the mortality rate globally. This study gives an overall idea about host-pathogen interaction, immune responses to COVID-19, recovery status of infection, targeted organs and complications associated, and comparison of post-infection immunity in convalescent subjects and non-infected individuals. The emergence of the variants and episodes of COVID-19 infections made the situation worsen. The timely introduction of vaccines and precautionary measures helped control the infection's severity. Later, the population that recovered from COVID-19 grew significantly. However, understanding the impact of healthcare issues resulting after infection is paramount for improving an individual's health status. It is now recognised that COVID-19 infection affects multiple organs and exhibits a broad range of clinical manifestations. So, post COVID-19 infection creates a high risk in individuals with already prevailing health complications. The identification of post-COVID-19-related health issues and their appropriate management is of greater importance to improving patient's quality of life. The persistence, sequelae and other medical complications that normally last from weeks to months after the recovery of the initial infection are involved with COVID-19. A multi-disciplinary approach is necessary for the development of preventive measures, techniques for rehabilitation and strategies for clinical management when it comes to long-term care.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Megha</LastName><ForeName>K B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Toxicology Division, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology (Govt. of India), Poojapura, Trivandrum, Kerala, 695 012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reshma</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Toxicology Division, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology (Govt. of India), Poojapura, Trivandrum, Kerala, 695 012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amir</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Toxicology Division, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology (Govt. of India), Poojapura, Trivandrum, Kerala, 695 012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishnan</LastName><ForeName>M J Ajai</ForeName><Initials>MJA</Initials><AffiliationInfo><Affiliation>Toxicology Division, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology (Govt. of India), Poojapura, Trivandrum, Kerala, 695 012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimona</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CSIR-Institute of Microbial Technology, Sector 39-A, Chandigarh, 160036, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academy of Scientific and Innovation Research (AcSIR), Ghaziabad, 201002, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alka</LastName><ForeName>Rao</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CSIR-Institute of Microbial Technology, Sector 39-A, Chandigarh, 160036, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academy of Scientific and Innovation Research (AcSIR), Ghaziabad, 201002, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohanan</LastName><ForeName>P V</ForeName><Initials>PV</Initials><Identifier Source="ORCID">0000-0001-9631-2938</Identifier><AffiliationInfo><Affiliation>Toxicology Division, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology (Govt. of India), Poojapura, Trivandrum, Kerala, 695 012, India. mohanpv10@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Neurobiol</MedlineTA><NlmUniqueID>8900963</NlmUniqueID><ISSNLinking>0893-7648</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 recovery</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-COVID complications</Keyword><Keyword MajorTopicYN="N">Post-COVID immunity</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>11</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>11</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>10</Day><Hour>23</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37817031</ArticleId><ArticleId IdType="doi">10.1007/s12035-023-03682-4</ArticleId><ArticleId IdType="pii">10.1007/s12035-023-03682-4</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Fehr AR, Perlman S (2015) Coronaviruses: an overview of their replication and pathogenesis, pp. 1&#x2013;23. https://doi.org/10.1007/978-1-4939-2438-7_1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-2438-7_1</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo PCY, Lau SKP, Lam CSF, Lau CCY, Tsang AKL, Lau JHN, Bai R, Teng JLL et al (2012) Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavi. J Virol 86:3995&#x2013;4008. https://doi.org/10.1128/JVI.06540-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06540-11</ArticleId><ArticleId IdType="pubmed">22278237</ArticleId><ArticleId IdType="pmc">3302495</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270&#x2013;273. https://doi.org/10.1038/s41586-020-2012-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId><ArticleId IdType="pmc">7095418</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19 . Accessed 22 Jun 2022</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497&#x2013;506. https://doi.org/10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId><ArticleId IdType="pmc">7159299</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Zhang Q, Wei P, Chen Z, Aviszus K, Yang J, Downing W, Jiang C et al (2021) The basis of a more contagious 501Y.V1 variant of SARS-CoV-2. Cell Res 31:720&#x2013;722. https://doi.org/10.1038/s41422-021-00496-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-021-00496-8</ArticleId><ArticleId IdType="pubmed">33893398</ArticleId><ArticleId IdType="pmc">8063779</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Wei P, Zhang Q, Chen Z, Aviszus K, Downing W, Peterson S, Reynoso L et al (2021) 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro. MAbs 13. https://doi.org/10.1080/19420862.2021.1919285</Citation></Reference><Reference><Citation>Aleem A, Akbar Samad AB, Slenker AK (2022) Emerging variants of SARS-CoV-2 And novel therapeutics against coronavirus (COVID-19).&#xa0; http://www.ncbi.nlm.nih.gov/pubmed/34033342</Citation></Reference><Reference><Citation>https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html . Accessed on 21 Sept 2023</Citation></Reference><Reference><Citation>Kopsidas I, Karagiannidou S, Kostaki EG, Kousi D, Douka E, Sfikakis PP et al (2022) Global distribution, dispersal patterns, and trend of several omicron subvariants of SARS-CoV-2 across the globe. Trav Med Infect Dis 7(11):373. https://doi.org/10.3390/tropicalmed7110373</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/tropicalmed7110373</ArticleId></ArticleIdList></Reference><Reference><Citation>Sah R, Rais MA, Mohanty A, Chopra H, Chandran D, Emran TB, Dhama K (2023) Omicron (B. 1.1. 529) variant and its subvariants and lineages may lead to another COVID-19 wave in the world?-An overview of current evidence and counteracting strategies. Int J Surg Open 18:100625</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijso.2023.100625</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou J, Lan W, Wu X, Zhao T, Duan B, Yang P et al (2022) Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events. Signal Transduct Targeted Ther 7(1):138. https://doi.org/10.1038/s41392-022-00992-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00992-2</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.webmed.com/covid/coronavirus-strains . Accessed on 20 Sept 23</Citation></Reference><Reference><Citation>https://www.ecdc.europa.eu/en/covid-19/variants-concern . Accessed on 20 Sept 23</Citation></Reference><Reference><Citation>Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN et al (2020) SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181(5):1016&#x2013;1035.e19</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.035</ArticleId><ArticleId IdType="pubmed">32413319</ArticleId><ArticleId IdType="pmc">7252096</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C et al (2020) Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 181:894&#x2013;904.e9. https://doi.org/10.1016/j.cell.2020.03.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.03.045</ArticleId><ArticleId IdType="pubmed">32275855</ArticleId><ArticleId IdType="pmc">7144619</ArticleId></ArticleIdList></Reference><Reference><Citation>Harmer D, Gilbert M, Borman R, Clark KL (2002) Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 532:107&#x2013;110. https://doi.org/10.1016/S0014-5793(02)03640-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(02)03640-2</ArticleId><ArticleId IdType="pubmed">12459472</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, Wang H (2020) The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of spike-based vaccine immunogens. Front Immunol 11. https://doi.org/10.3389/fimmu.2020.576622</Citation></Reference><Reference><Citation>Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q (2020) Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367:1444&#x2013;1448. https://doi.org/10.1126/science.abb2762</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb2762</ArticleId><ArticleId IdType="pubmed">32132184</ArticleId><ArticleId IdType="pmc">7164635</ArticleId></ArticleIdList></Reference><Reference><Citation>Vankadari N (2020) Structure of furin protease binding to SARS-CoV-2 spike glycoprotein and implications for potential targets and virulence. J Phys Chem Lett 11:6655&#x2013;6663. https://doi.org/10.1021/acs.jpclett.0c01698</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jpclett.0c01698</ArticleId><ArticleId IdType="pubmed">32787225</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;rd M, Faustova I, Loog M (2020) The sequence at Spike S1/S2 site enables cleavage by furin and phospho-regulation in SARS-CoV2 but not in SARS-CoV1 or MERS-CoV. Sci Rep 10:16944. https://doi.org/10.1038/s41598-020-74101-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-74101-0</ArticleId><ArticleId IdType="pubmed">33037310</ArticleId><ArticleId IdType="pmc">7547067</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Qiu Y, Li J-Y, Zhou Z-J, Liao C-H, Ge X-Y (2020) A unique protease cleavage site predicted in the spike protein of the novel pneumonia coronavirus (2019-nCoV) potentially related to viral transmissibility. Virol Sin 35:337&#x2013;339. https://doi.org/10.1007/s12250-020-00212-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-020-00212-7</ArticleId><ArticleId IdType="pubmed">32198713</ArticleId><ArticleId IdType="pmc">7091172</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynne BM, Zou L, Linck V, Hoover RS, Ma H-P, Eaton DC (2017) Regulation of lung epithelial sodium channels by cytokines and chemokines. Front Immunol 8. https://doi.org/10.3389/fimmu.2017.00766</Citation></Reference><Reference><Citation>Papa G, Mallery DL, Albecka A, Welch LG, Cattin-Ortol&#xe1; J, Luptak J, Paul D, McMahon HT et al (2021) Furin cleavage of SARS-CoV-2 spike promotes but is not essential for infection and cell-cell fusion. PLOS Pathog 17:e1009246. https://doi.org/10.1371/journal.ppat.1009246</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009246</ArticleId><ArticleId IdType="pubmed">33493182</ArticleId><ArticleId IdType="pmc">7861537</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P (2005) Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci 102:11876&#x2013;11881. https://doi.org/10.1073/pnas.0505577102</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0505577102</ArticleId><ArticleId IdType="pubmed">16081529</ArticleId><ArticleId IdType="pmc">1188015</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang I-C, Bosch BJ, Li F, Li W, Lee KH, Ghiran S, Vasilieva N, Dermody TS et al (2006) SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J Biol Chem 281:3198&#x2013;3203. https://doi.org/10.1074/jbc.M508381200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M508381200</ArticleId><ArticleId IdType="pubmed">16339146</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Luo S, Libby P, Shi G-P (2020) Cathepsin L-selective inhibitors: a potentially promising treatment for COVID-19 patients. Pharmacol Ther 213:107587. https://doi.org/10.1016/j.pharmthera.2020.107587</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2020.107587</ArticleId><ArticleId IdType="pubmed">32470470</ArticleId><ArticleId IdType="pmc">7255230</ArticleId></ArticleIdList></Reference><Reference><Citation>Zachary I (2014) Neuropilins: role in signalling, angiogenesis and disease, pp. 37&#x2013;70. https://doi.org/10.1159/000354169</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000354169</ArticleId></ArticleIdList></Reference><Reference><Citation>Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E (2020) The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res 176:104742. https://doi.org/10.1016/j.antiviral.2020.104742</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104742</ArticleId><ArticleId IdType="pubmed">32057769</ArticleId><ArticleId IdType="pmc">7114094</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Buck M (2021) Neuropilin-1 assists SARS-CoV-2 infection by stimulating the separation of spike protein S1 and S2. Biophys J 120:2828&#x2013;2837. https://doi.org/10.1016/j.bpj.2021.05.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2021.05.026</ArticleId><ArticleId IdType="pubmed">34087218</ArticleId><ArticleId IdType="pmc">8169233</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, van der Meer F, Kallio K et al (2020) Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 370:856&#x2013;860. https://doi.org/10.1126/science.abd2985</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd2985</ArticleId><ArticleId IdType="pubmed">33082293</ArticleId><ArticleId IdType="pmc">7857391</ArticleId></ArticleIdList></Reference><Reference><Citation>Madu IG, Chu VC, Lee H, Regan AD, Bauman BE, Whittaker GR (2007) Heparan sulfate is a selective attachment factor for the avian coronavirus infectious bronchitis virus Beaudette. Avian Dis 51:45&#x2013;51. https://doi.org/10.1637/0005-2086(2007)051[0045:HSIASA]2.0.CO;2</Citation><ArticleIdList><ArticleId IdType="doi">10.1637/0005-2086(2007)051[0045:HSIASA]2.0.CO;2</ArticleId><ArticleId IdType="pubmed">17461266</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe R, Sawicki SG, Taguchi F (2007) Heparan sulfate is a binding molecule but not a receptor for CEACAM1-independent infection of murine coronavirus. Virology 366:16&#x2013;22. https://doi.org/10.1016/j.virol.2007.06.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2007.06.034</ArticleId><ArticleId IdType="pubmed">17692355</ArticleId></ArticleIdList></Reference><Reference><Citation>Milewska A, Zarebski M, Nowak P, Stozek K, Potempa J, Pyrc K (2014) Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells. J Virol 88:13221&#x2013;13230. https://doi.org/10.1128/JVI.02078-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02078-14</ArticleId><ArticleId IdType="pubmed">25187545</ArticleId><ArticleId IdType="pmc">4249106</ArticleId></ArticleIdList></Reference><Reference><Citation>Clausen TM, Sandoval DR, Spliid CB, Pihl J, Perrett HR, Painter CD et al (2020) SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell 183(4):1043&#x2013;1057.e15. https://doi.org/10.1016/j.cell.2020.09.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.033</ArticleId><ArticleId IdType="pubmed">32970989</ArticleId><ArticleId IdType="pmc">7489987</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44&#x2013;57. https://doi.org/10.1038/nprot.2008.211</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2008.211</ArticleId><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan K, Huang C, Lokugamage K, Kamitani W, Ikegami T, Tseng C-TK, Makino S (2008) Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J Virol 82:4471&#x2013;4479. https://doi.org/10.1128/JVI.02472-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02472-07</ArticleId><ArticleId IdType="pubmed">18305050</ArticleId><ArticleId IdType="pmc">2293030</ArticleId></ArticleIdList></Reference><Reference><Citation>Sola I, Almaz&#xe1;n F, Z&#xfa;&#xf1;iga S, Enjuanes L (2015) Continuous and discontinuous RNA synthesis in coronaviruses. Annu Rev Virol 2:265&#x2013;288. https://doi.org/10.1146/annurev-virology-100114-055218</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-100114-055218</ArticleId><ArticleId IdType="pubmed">26958916</ArticleId><ArticleId IdType="pmc">6025776</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM et al (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583(7816):459&#x2013;468. https://doi.org/10.1038/s41586-020-2286-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2286-9</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId><ArticleId IdType="pmc">7431030</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao H, Song Y, Chen Y, Wu N, Xu J, Sun C, Zhang J, Weng T et al (2020) Molecular architecture of the SARS-CoV-2 virus. Cell 183:730&#x2013;738.e13. https://doi.org/10.1016/j.cell.2020.09.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.018</ArticleId><ArticleId IdType="pubmed">32979942</ArticleId><ArticleId IdType="pmc">7474903</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendon&#xe7;a L, Howe A, Gilchrist JB, Sheng Y, Sun D, Knight ML, Zanetti-Domingues LC, Bateman B et al (2021) Correlative multi-scale cryo-imaging unveils SARS-CoV-2 assembly and egress. Nat Commun 12:4629. https://doi.org/10.1038/s41467-021-24887-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24887-y</ArticleId><ArticleId IdType="pubmed">34330917</ArticleId><ArticleId IdType="pmc">8324836</ArticleId></ArticleIdList></Reference><Reference><Citation>Eymieux S, Uzbekov R, Rouill&#xe9; Y, Blanchard E, Hourioux C, Dubuisson J, Belouzard S, Roingeard P (2021) Secretory vesicles are the principal means of SARS-CoV-2 Egress. Cells 10:2047. https://doi.org/10.3390/cells10082047</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10082047</ArticleId><ArticleId IdType="pubmed">34440816</ArticleId><ArticleId IdType="pmc">8393858</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanifer ML, Pervolaraki K, Boulant S (2019) Differential regulation of type I and type III interferon signaling. Int J Mol Sci 20:1445. https://doi.org/10.3390/ijms20061445</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20061445</ArticleId><ArticleId IdType="pubmed">30901970</ArticleId><ArticleId IdType="pmc">6471306</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JS, Warrington R, Watson W, Kim HL (2018) An introduction to immunology and immunopathology. Allergy, Asthma Clin Immunol [Internet] 14(2):1&#x2013;10. https://doi.org/10.1186/s13223-018-0278-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13223-018-0278-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaplin DD (2010) Overview of the immune response. J Allergy Clin Immunol [Internet] 125(2 Suppl 2):S3 Available from: /pmc/articles/PMC2923430/</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2009.12.980</ArticleId><ArticleId IdType="pubmed">20176265</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapter 23. The immune system &#x2013; concepts of biology &#x2013; 1st Canadian Edition [Internet]. [cited 2022 Jul 30]. Available from: https://opentextbc.ca/biology/part/chapter-23-the-immune-system/</Citation></Reference><Reference><Citation>Liu R, Wang Y, Li J, Han H, Xia Z, Liu F, Wu K, Yang L, Liu X, Zhu C (2020) Decreased T cell populations contribute to the increased severity of COVID-19. Clin Chim Acta 508:110&#x2013;114</Citation></Reference><Reference><Citation>Characteristics of SARS-CoV-2 and COVID-19 | Nature Reviews Microbiology. (n.d.). Retrieved February 7, 2023, from https://www.nature.com/articles/s41579-020-00459-7</Citation></Reference><Reference><Citation>SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity | Nature Communications. (n.d.). Retrieved February 7, 2023, from https://www.nature.com/articles/s41467-022-30088-y</Citation></Reference><Reference><Citation>Kudlay D, Kofiadi I, Khaitov M (2022) Peculiarities of the t cell immune response in COVID-19. Vaccines 10(2):2. https://doi.org/10.3390/vaccines10020242</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10020242</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuki K, Fujiogi M, Koutsogiannaki S (2020) COVID-19 pathophysiology: a review. Clin Immunol 215:108427. https://doi.org/10.1016/j.clim.2020.108427</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108427</ArticleId><ArticleId IdType="pubmed">32325252</ArticleId><ArticleId IdType="pmc">7169933</ArticleId></ArticleIdList></Reference><Reference><Citation>Guihot A, Litvinova E, Autran B, Debr&#xe9; P, Vieillard V (2020) Cell-mediated immune responses to COVID-19 infection. Front Immunol 11.&#xa0; https://www.frontiersin.org/articles/10.3389/fimmu.2020.01662</Citation></Reference><Reference><Citation>The humoral response and antibodies against SARS-CoV-2 infection | Nature Immunology. (n.d.). Retrieved February 7, 2023, from https://www.nature.com/articles/s41590-022-01248-5</Citation></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E et al (2020) Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network &#x2014; United States, March&#x2013;June 2020. MMWR Morb Mortal Wkly Rep 69(30):993&#x2013;998. https://doi.org/10.15585/MMWR.MM6930E1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/MMWR.MM6930E1</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId><ArticleId IdType="pmc">7392393</ArticleId></ArticleIdList></Reference><Reference><Citation>Barman MP, Rahman T, Bora K, Borgohain C (2020) COVID-19 pandemic and its recovery time of patients in India: A pilot study. Diabetes Metab Syndr: Clin Res Rev 14(5):1205&#x2013;1211. https://doi.org/10.1016/j.dsx.2020.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.07.004</ArticleId></ArticleIdList></Reference><Reference><Citation>George N, Tyagi NK, Prasad JB (2021) COVID-19 pandemic and its average recovery time in Indian states. Clin Epidemiol Glob Health 11. https://doi.org/10.1016/j.cegh.2021.100740</Citation></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P (2021) Long covid - mechanisms, risk factors, and management. BMJ 374. https://doi.org/10.1136/bmj.n1648</Citation></Reference><Reference><Citation>Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203(2):631&#x2013;637. https://doi.org/10.1002/path.1570</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1570</ArticleId><ArticleId IdType="pubmed">15141377</ArticleId><ArticleId IdType="pmc">7167720</ArticleId></ArticleIdList></Reference><Reference><Citation>Go&#xeb;rtz YMJ, van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, Houben-Wilke S, Burtin C et al (2020) Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res 6(4):542&#x2013;2020. https://doi.org/10.1183/23120541.00542-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00542-2020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal M, Abo Omirah M, Hussein A, Saeed H (2021a) Assessment and characterization of post-COVID-19 manifestations. Int J Clin Pract 75(3). https://doi.org/10.1111/ijcp.13746</Citation></Reference><Reference><Citation>Frontera JA, Yang D, Lewis A, Patel P, Medicherla C et al (2021) A prospective study of long-term outcomes among hospitalised COVID-19 patients with and without neurological complications. J Neurol Sci 426. https://doi.org/10.1016/j.jns.2021.117486</Citation></Reference><Reference><Citation>Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, Heightman M, Hillman TE et al (2021) Long-COVID&#x2019;: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 76(4):396&#x2013;398. https://doi.org/10.1136/thoraxjnl-2020-215818</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215818</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F (2020) Persistent symptoms in patients after acute COVID-19. JAMA - J Am Med Assoc 324(6):603&#x2013;605. https://doi.org/10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, Shchendrygina A, Escher F et al (2020) Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 5(11):1265&#x2013;1273. https://doi.org/10.1001/jamacardio.2020.3557</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.3557</ArticleId><ArticleId IdType="pubmed">32730619</ArticleId><ArticleId IdType="pmc">7385689</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, Dong W (2021) Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect 27(1):89&#x2013;95. https://doi.org/10.1016/j.cmi.2020.09.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.023</ArticleId><ArticleId IdType="pubmed">32979574</ArticleId></ArticleIdList></Reference><Reference><Citation>Valiente-De Santis L, P&#xe9;rez-Camacho I, Sobrino B, ValientGonzalez GE, Ruiz-Mesa JD, Plata A, Reguera JM (2020) Title: clinical and immunoserological status 12 weeks after infection with COVID-19. MedRxiv. https://doi.org/10.1101/2020.10.06.20206060</Citation></Reference><Reference><Citation>Poyraz B&#xc7;, Poyraz CA, Olgun Y, G&#xfc;rel &#xd6;, Alkan S, &#xd6;zdemir YE, Balkan &#x130;&#x130;, Karaali R (2021) Psychiatric morbidity and protracted symptoms after COVID-19. Psychiatry Res 295. https://doi.org/10.1016/j.psychres.2020.113604</Citation></Reference><Reference><Citation>Paderno A, Mattavelli D, Rampinelli V, Grammatica A, Raffetti E, Tomasoni M, Gualtieri T, Taboni S et al (2020) Olfactory and gustatory outcomes in COVID-19: a prospective evaluation in nonhospitalised subjects. Otolaryngol - Head Neck Surg (United States) 163(6):1144&#x2013;1149. https://doi.org/10.1177/0194599820939538</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599820939538</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasoni D, Bai F, Castoldi R, Barbanotti D, Falcinella C, Mul&#xe8; G, Mondatore D, Tavelli A et al (2021) Anxiety and depression symptoms after virological clearance of COVID-19: a cross-sectional study in Milan, Italy. J Med Virol 93(2):1175&#x2013;1179. https://doi.org/10.1002/jmv.26459</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26459</ArticleId><ArticleId IdType="pubmed">32841387</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao YM, Shang YM, Song WB, Li QQ, Xie H, Xu QF, Jia JL, Li LM et al (2020) Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine 25. https://doi.org/10.1016/j.eclinm.2020.100463</Citation></Reference><Reference><Citation>Savarraj JP, Burkett AB, Hinds SN, Paz AS, Assing A, Juneja S, Delevati Colpo G, Torres LF et al (2020) Three-month outcomes in hospitalised COVID-19 patients. MedRxiv. https://doi.org/10.1101/2020.10.16.20211029</Citation></Reference><Reference><Citation>Islam MF, Cotler J, Jason LA (2020) Post-viral fatigue and COVID-19: lessons from past epidemics. Fatigue: Biomed Health Behav 8(2):61&#x2013;69. https://doi.org/10.1080/21641846.2020.1778227</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21641846.2020.1778227</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Jones K, Dunne J, Mooney A et al (2020) Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One 15. https://doi.org/10.1371/journal.pone.0240784</Citation></Reference><Reference><Citation>Wostyn P (2021) COVID-19 and chronic fatigue syndrome: is the worst yet to come? Med Hypotheses 146. https://doi.org/10.1016/j.mehy.2020.110469</Citation></Reference><Reference><Citation>Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M, Li Y, Cao Y et al (2021) Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology 299(1):E177&#x2013;E186. https://doi.org/10.1148/RADIOL.2021203153</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/RADIOL.2021203153</ArticleId><ArticleId IdType="pubmed">33497317</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Lv F, Huang Y, Xiao K (2021) Follow-up study of the chest CT characteristics of COVID-19 survivors seven months after recovery. Front Med 8. https://doi.org/10.3389/FMED.2021.636298</Citation></Reference><Reference><Citation>McElvaney OJ, McEvoy NL, McElvaney OF, Carroll TP, Murphy et al (2020) Characterisation of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med 202(6):812&#x2013;821. https://doi.org/10.1164/RCCM.202005-1583OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/RCCM.202005-1583OC</ArticleId><ArticleId IdType="pubmed">32584597</ArticleId><ArticleId IdType="pmc">7491404</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajpal S, Tong MS, Borchers J, Zareba KM, Obarski TP, Simonetti OP, Daniels CJ (2021) Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol 6(1):116&#x2013;118. https://doi.org/10.1001/JAMACARDIO.2020.4916</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMACARDIO.2020.4916</ArticleId><ArticleId IdType="pubmed">32915194</ArticleId></ArticleIdList></Reference><Reference><Citation>Needham EJ, Chou SHY, Coles AJ, Menon DK (2020) Neurological implications of COVID-19 infections. Neurocrit Care 32(3):667&#x2013;671. https://doi.org/10.1007/S12028-020-00978-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S12028-020-00978-4</ArticleId><ArticleId IdType="pubmed">32346843</ArticleId><ArticleId IdType="pmc">7188454</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen W, Su W, Tang H, Le W, Zhang X, Zheng Y, Liu X, Xie L et al (2020) Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov 6(1). https://doi.org/10.1038/s41421-020-0168-9</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ (2023) Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 21(3):133&#x2013;146</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId><ArticleId IdType="pmc">9839201</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavda VP, Apostolopoulos V (2021) Mucormycosis &#x2013; an opportunistic infection in the aged immunocompromised individual: a reason for concern in COVID-19. Maturitas. https://doi.org/10.1016/j.maturitas.2021.07.009</Citation></Reference><Reference><Citation>Taquet M, Dercon Q, Harrison PJ (2021) Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. MedRxiv 2021(10):26.21265508. https://doi.org/10.1101/2021.10.26.21265508</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.10.26.21265508</ArticleId></ArticleIdList></Reference><Reference><Citation>http://covid19.who.int . Accessed on 20 Sept 2023</Citation></Reference><Reference><Citation>https://www.who.int/news/item/17-06-2022-interim-statement-on%2D%2Dthe-composition-of-current-COVID-19-vaccines . Accessed 20 Sept 2023</Citation></Reference><Reference><Citation>St&#xe5;hlberg M, Reistam U, Fedorowski A, Villacorta H, Horiuchi Y, Bax J, Pitt B, Matskeplishvili S et al (2021) Post-COVID-19 tachycardia syndrome: a distinct phenotype of post-acute COVID-19 syndrome. Am J Med 134:1451&#x2013;1456. https://doi.org/10.1016/j.amjmed.2021.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2021.07.004</ArticleId><ArticleId IdType="pubmed">34390682</ArticleId><ArticleId IdType="pmc">8356730</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A&#x2019;Court C, Buxton M, Husain L (2020) Management of post-acute COVID-19 in primary care. BMJ m3026. https://doi.org/10.1136/bmj.m3026</Citation></Reference><Reference><Citation>Shah W, Hillman T, Playford ED, Hishmeh L (2021) Managing the long term effects of COVID-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ n136. https://doi.org/10.1136/bmj.n136</Citation></Reference><Reference><Citation>Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, Walshaw C, Kemp S et al (2021) Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol 93:1013&#x2013;1022. https://doi.org/10.1002/jmv.26368</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26368</ArticleId><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra V, Flanders SA, O&#x2019;Malley M, Malani AN, Prescott HC (2021) Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med 174:576&#x2013;578. https://doi.org/10.7326/M20-5661</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-5661</ArticleId><ArticleId IdType="pubmed">33175566</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L et al (2021) 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 397:220&#x2013;232. https://doi.org/10.1016/S0140-6736(20)32656-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId><ArticleId IdType="pmc">7833295</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, Noel A, Gunning S et al (2021) Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax 76:399&#x2013;401. https://doi.org/10.1136/thoraxjnl-2020-216086</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216086</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharat A, Querrey M, Markov NS, Kim S, Kurihara C, Garza-Castillon R, Manerikar A, Shilatifard A et al (2020) Lung transplantation for patients with severe COVID-19. Sci Transl Med 12. https://doi.org/10.1126/scitranslmed.abe4282</Citation></Reference><Reference><Citation>Cui S, Chen S, Li X, Liu S, Wang F (2020) Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 18:1421&#x2013;1424. https://doi.org/10.1111/jth.14830</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14830</ArticleId><ArticleId IdType="pubmed">32271988</ArticleId><ArticleId IdType="pmc">7262324</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Shi L, Wang Y, Zhang J, Huang L et al (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respirat Med 8:420&#x2013;422 https://pubmed.ncbi.nlm.nih.gov/32085846/</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30076-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo X, Jian W, Su Z, Chen M, Peng H et al (2020) Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. EurRespirat J 55:2001217 https://pubmed.ncbi.nlm.nih.gov/32381497/</Citation></Reference><Reference><Citation>https://www.lung.org/lung-health-diseases/lung-disease-lookup/ards</Citation></Reference><Reference><Citation>Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C et al (2021) Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect 27:258&#x2013;263. https://doi.org/10.1016/j.cmi.2020.09.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.052</ArticleId><ArticleId IdType="pubmed">33031948</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain U (2020) Eff ect of COVID-19 on the organs. Cureus 12:e9540 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470660/ . Accessed 19 Sept 2023</Citation><ArticleIdList><ArticleId IdType="pubmed">32905500</ArticleId><ArticleId IdType="pmc">7470660</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta JL, Calcaterra G, Bassareo PP (2020) COVID-19, thromboembolic risk, and Virchow&#x2019;s triad: lesson from the past. Clin Cardiol 43:1362&#x2013;1367 https://pubmed.ncbi.nlm.nih.gov/33176009/</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.23460</ArticleId><ArticleId IdType="pubmed">33176009</ArticleId><ArticleId IdType="pmc">7724210</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng YY, Ma YT, Zhang JY, Xie X (2020) COVID-19 and the cardiovascular system. Nat Rev Cardiol 17:259&#x2013;260 https://pubmed.ncbi.nlm.nih.gov/32139904/</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-0360-5</ArticleId><ArticleId IdType="pubmed">32139904</ArticleId><ArticleId IdType="pmc">7095524</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni W, Yang X, Yang D, Bao J, Li R et al (2020) Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care 24:1&#x2013;10 https://pubmed.ncbi.nlm.nih.gov/32660650/</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03120-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Peleg Y, Kudose S, D&#x2019;Agati V, Siddall E, Ahmad S, Nickolas T, Kisselev S, Gharavi A et al (2020) Acute kidney injury due to collapsing glomerulopathy following COVID-19 infection. Kidney Int Rep 5:940&#x2013;945. https://doi.org/10.1016/j.ekir.2020.04.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2020.04.017</ArticleId><ArticleId IdType="pubmed">32346659</ArticleId><ArticleId IdType="pmc">7186120</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens JS, King KL, Robbins-Juarez SY, Khairallah P, Toma K et al (2020) High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy. PLoS One 15:e0244131. https://doi.org/10.1371/journal.pone.0244131</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0244131</ArticleId><ArticleId IdType="pubmed">33370368</ArticleId><ArticleId IdType="pmc">7769434</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Hayek SS, Wang W, Chan L, Mathews KS et al (2020) Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med 180:1436. https://doi.org/10.1001/jamainternmed.2020.3596</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.3596</ArticleId><ArticleId IdType="pubmed">32667668</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhaveri KD, Meir LR, Flores Chang BS, Parikh R, Wanchoo R, Barilla-LaBarca ML, Bijol V, Hajizadeh N (2020) Thrombotic microangiopathy in a patient with COVID-19. Kidney Int 98:509&#x2013;512. https://doi.org/10.1016/j.kint.2020.05.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.05.025</ArticleId><ArticleId IdType="pubmed">32525010</ArticleId><ArticleId IdType="pmc">7276225</ArticleId></ArticleIdList></Reference><Reference><Citation>Velez JCQ, Caza T, Larsen CP (2020) COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nat Rev Nephrol 16:565&#x2013;567. https://doi.org/10.1038/s41581-020-0332-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-020-0332-3</ArticleId><ArticleId IdType="pubmed">32753739</ArticleId><ArticleId IdType="pmc">7400750</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeffer Baum B, North CS (2020) Mental health and the Covid-19 pandemic. N Engl J Med 383:510&#x2013;512</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2008017</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Xu X (2020) scRNA-seq profi ling of human testes reveals the presence of the ACE2 receptor, a target for SARS-CoV-2 infection in spermatogonia, leydig and sertoli Cells. Cells 9:920 https://pubmed.ncbi.nlm.nih.gov/32283711/</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9040920</ArticleId><ArticleId IdType="pubmed">32283711</ArticleId><ArticleId IdType="pmc">7226809</ArticleId></ArticleIdList></Reference><Reference><Citation>Batiha O, Al-Deeb T, Al-zoubi EA, Alsharu E (2020) Impact of COVID-19 and other viruses on reproductive health. Andrologia 52:e13791 https://pubmed.ncbi.nlm.nih.gov/32790205/</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/and.13791</ArticleId><ArticleId IdType="pubmed">32790205</ArticleId><ArticleId IdType="pmc">7435575</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan C, Li K, Ding Y, Lu WL, Wang J (2020) ACE2 expression in kidney and testis may cause kidney and testis damage after 2019-nCoV infection. MedRxiv</Citation></Reference><Reference><Citation>Foo CC, Goon ATJ, Leow YH et al (2006) Adverse skin reactions to personal protective equipment against severe acute respiratory syndrome&#x2014;a descriptive study in Singapore. Contact Dermatitis 55:291&#x2013;294 https://pubmed.ncbi.nlm.nih.gov/17026695/</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0536.2006.00953.x</ArticleId><ArticleId IdType="pubmed">17026695</ArticleId><ArticleId IdType="pmc">7162267</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia J, Tong J, Liu M, Shen Y, Guo D et al (2020) Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol 92:589&#x2013;594 https://pubmed.ncbi.nlm.nih.gov/32100876/</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25725</ArticleId><ArticleId IdType="pubmed">32100876</ArticleId><ArticleId IdType="pmc">7228294</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P, Duan F, Luo C et al (2020) Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei province, China. JAMA Ophthalmol 138:575&#x2013;578 https://pubmed.ncbi.nlm.nih.gov/32232433/</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2020.1291</ArticleId><ArticleId IdType="pubmed">32232433</ArticleId><ArticleId IdType="pmc">7110919</ArticleId></ArticleIdList></Reference><Reference><Citation>Umashankar A, Prabhu P (2020) Effect of Covid-19 on individuals with hearing impairment in India. J Clin Diagnos Res&#xa0;14(8):10&#x2013;7860</Citation></Reference><Reference><Citation>Lai T, Xiang F, Zeng J, Huang Y, Jia L et al (2020) Reliability of induced sputum test is greater than that of throat swab test for detecting SARSCoV- 2 in patients with COVID-19: a multi-center cross-sectional study. Virulence 11:1394&#x2013;1401 https://pubmed.ncbi.nlm.nih.gov/33073676/</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21505594.2020.1831342</ArticleId><ArticleId IdType="pubmed">33073676</ArticleId><ArticleId IdType="pmc">7575004</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z, Diao B, Wang R, Wang G, Wang C et al (2020) The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes. MedRxiv</Citation></Reference><Reference><Citation>Zhang C, Shi L, Wang FS (2020) Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 5:428&#x2013;430 https://pubmed.ncbi.nlm.nih.gov/32145190/</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30057-1</ArticleId><ArticleId IdType="pubmed">32145190</ArticleId><ArticleId IdType="pmc">7129165</ArticleId></ArticleIdList></Reference><Reference><Citation>Inamdar S, Benias PC, Liu Y, Sejpal DV, Satapathy SK et al (2020) Prevalence, risk factors, and outcomes of hospitalized patients with COVID-19 presenting as acute pancreatitis. Gastroenterology 159:2226&#x2013;2228.e2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448741/</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.08.044</ArticleId><ArticleId IdType="pubmed">32860787</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z (2020) ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol 18(9):2128&#x2013;30</Citation></Reference><Reference><Citation>Deisl C, Simonin A, Anderegg M, Albano G, Kovacs G et al (2013) Sodium/ hydrogen exchanger NHA2 is critical for insulin secretion in &#x3b2;-cells. Proc Natl Acad Sci U S A 110:10004&#x2013;10009 https://pubmed.ncbi.nlm.nih.gov/23720317/</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1220009110</ArticleId><ArticleId IdType="pubmed">23720317</ArticleId><ArticleId IdType="pmc">3683798</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Zhou W, Xu W (2021) Thyroid function analysis in 50 patients with COVID-19: a retrospective study. Thyroid 31:8&#x2013;11 https://pubmed.ncbi.nlm.nih.gov/32600165/ . Accessed 20 Sept 2023</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2020.0363</ArticleId><ArticleId IdType="pubmed">32600165</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkattawy S, Alyacoub R, Ayad S, Pandya M, Eckman A (2020) A novel case of hypoparathyroidism secondary to SARS-CoV-2 infection. Cureus 12:e10097 https://pubmed.ncbi.nlm.nih.gov/33005518/ . Accessed 20 Sept 2023</Citation><ArticleIdList><ArticleId IdType="pubmed">33005518</ArticleId><ArticleId IdType="pmc">7522187</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti P, Ronconi G, Caraffa A, Gallenga C, Ross R, Frydas I, Kritas S (n.d.) Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 34:327&#x2013;331. https://doi.org/10.23812/CONTI-E</Citation></Reference><Reference><Citation>Ramos-Casals JR, Brahmer MK, Callahan A, Flores-Ch&#xe1;vez N, Keegan MA, Khamashta O, Lambotte X, Mariette A et al (2020) Su&#xe1;rez-Almazor, Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Prim 6:38. https://doi.org/10.1038/s41572-020-0160-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-020-0160-6</ArticleId><ArticleId IdType="pubmed">32382051</ArticleId></ArticleIdList></Reference><Reference><Citation>Rampuria P, Lang ML (2018) Regulation of humoral immunity by CD1d-restricted natural killer T cells. Immunol: Immunotoxicol Immunopathol Immunotherapy 1:55&#x2013;73</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-809819-6.00005-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE et al (2021) Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science [Internet] 371:6529 Available from: https://pubmed.ncbi.nlm.nih.gov/33408181/ . Accessed 5 Feb 2021</Citation></Reference><Reference><Citation>Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD et al (2021) Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell [Internet] 184(1):169&#x2013;183.e17 Available from: https://pubmed.ncbi.nlm.nih.gov/33296701/ . Accessed 7 Jan 2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.11.029</ArticleId><ArticleId IdType="pubmed">33296701</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M et al (2021) Evolution of antibody immunity to SARS-CoV-2. bioRxiv [Internet] 4 Available from: https://pubmed.ncbi.nlm.nih.gov/33173867/ . Accessed 4 Jan 2021</Citation></Reference><Reference><Citation>Zuo J, Dowell AC, Pearce H, Verma K, Long HM, Begum J et al (2021) Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat Immunol [Internet] 22(5):620&#x2013;626 Available from: https://pubmed.ncbi.nlm.nih.gov/33674800/ . Accessed 30 Jul 2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00902-8</ArticleId><ArticleId IdType="pubmed">33674800</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen-Contant P, Embong AK, Kanagaiah P, Chaves FA, Yang H, Branche AR et al (2020) S Protein-reactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit. mBio [Internet] 11(5):1&#x2013;11 Available from: /pmc/articles/PMC7520599/</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>